Piyanuch Kongtim
•Associate Clinical Professor, Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of California, Irvine
•Ad Hoc Statistician, UCI Chao Comprehensive Cancer Center Biostatistics Shared Resource (BSR)
Biography
Piyanuch Kongtim, M.D., Ph.D., is Associate Clinical Professor in the Division of Hematology/Oncology, Department of Medicine, School of Medicine at the University of California, Irvine. Kongtim received a Ph.D. in Clinical Epidemiology and Biostatistics from Thammasat University in Thailand, where she also completed her medical degree with First Class Honors and her hematology residency training. She completed a postdoctoral research fellowship in the Department of Stem Cell Transplantation and Cellular Therapy at The University of Texas MD Anderson Cancer Center.
Kongtim's research focuses on allogeneic hematopoietic stem cell transplantation, with particular emphasis on haploidentical transplantation, donor selection, and the development of prognostic models to predict transplant outcomes. She has developed several novel risk stratification tools, including the Hematopoietic Cell Transplant-Composite Risk (HCT-CR) model and disease-specific risk models for acute myeloid leukemia. Her work has contributed to consensus guidelines on donor-specific anti-HLA antibodies in haploidentical transplantation through the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. She serves as principal investigator or co-investigator on multiple clinical trials investigating conditioning regimens, graft-versus-host disease prevention, and cellular therapy approaches in stem cell transplantation.
Kongtim has authored over 60 peer-reviewed publications and numerous abstracts presented at international conferences. She serves on the editorial board of Frontiers in Immunology and as a reviewer for multiple transplantation and hematology journals. She received the Thammasat University Distinguished Alumni Award in 2025 and the Thammasat University Outstanding Dissertation Award in 2021. Kongtim also received two Thai Royal Decoration Awards from His Majesty the King of Thailand. In addition to her clinical and research roles, she serves as an ad hoc statistician for the UCI Chao Comprehensive Cancer Center Biostatistics Shared Resource.
Return to topEducation
- M.D., Faculty of Medicine, Thammasat University, 2004
- Ph.D. in Clinical Epidemiology and Biostatistics, Faculty of Medicine, Thammasat University, 2019
- Diploma in Clinical Statistics, Faculty of Medicine, Thammasat University, 2018
- Diploma in Clinical Epidemiology, Faculty of Medicine, Thammasat University, 2018
Distinctions
- Thai Royal Decoration Award: Commander (Third Class) of the Most Noble Order of the Crown of Thailand, 2015
- Postdoctoral Research Fellowship, 2012-2014
- Thai Royal Decoration Award: Companion (Fourth Class) of the Most Exalted Order of the White Elephant, 2010
- Thammasat University Distinguished Alumni Award, 2025
- American Society of Hematology Abstract Achievement Award, 2013
- Thammasat University Outstanding Dissertation Award, 2021
- Clinical Instructor of the Year, 2015
- Young Investigator Award, 2015
Areas of Expertise
- Hematopoietic Cell Transplantation
- Haploidentical Donor Selection
- Acute Myeloid Leukemia Outcomes
- Graft-Versus-Host Disease Prevention
- Donor-Specific Anti-HLA Antibodies
- Natural Killer Cell Therapy
- Transplant Survival Prediction Models
Recent Publications
- Chumnumsiriwath P., Bellman P., Tran M.-H., Golly C., Ciurea S.O., Kongtim P., “Impact of Stem Cell Mobilization with Chemotherapy Versus G-CSF Alone for Multiple Myeloma Patients with Suboptimal Response Before Autologous Stem Cell Transplant” (opens in new tab), Clinical Lymphoma Myeloma and Leukemia, vol. 26, pp. e569-e576, 2026.
- Kongtim P, Chumnumsiriwath P, Vittayawacharin P, Jeyakumar D, Lee BJ, Doh J, Griffin SP, Van Etten RA, Ciurea S, “Budesonide, Added to PTCy-Based Regimen, for Prevention of Acute GI GVHD After Allogeneic Stem Cell Transplantation” (opens in new tab), American Journal of Hematology, vol. 100, no. 3, pp. 383-392, 2025.
- Kongtim P, Chumnumsiriwath P, Vittayawacharin P, Lee BJ, Doh J, Griffin SP, Van Etten RA, Ciurea SO, “Results of a Prospective Observational Study Using Budesonide, Added to Ptcy-Based Gvhd Prophylaxis, for Prevention of Acute GI Gvhd after Allogeneic Transplantation and Comparison with CIBMTR Control”, Transplantation and Cellular Therapy, vol. 31, no. 2, Supplement, pp. S287, 2025.
- Wannaphut C., Chumnumsiriwath P., Ciurea S.O., Kongtim P., “Outcomes of fludarabine-melphalan versus fludarabine-busulfan reduced-intensity conditioning regimens for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A systematic review and meta-analysis” (opens in new tab), Cancer, vol. 131, 2025.
- Kongtim P., Ciurea S.O., “When the first graft fails: a strategic approach to donor selection for second transplant” (opens in new tab), Haematologica, vol. 111, pp. 444-445, 2025.
- Lee BJ, Griffin SP, Doh J, Chan A, Ciurea SO, Jeyakumar D, Fleischman AG, Naqvi K, Pannunzio NR, O'Brien S, Kongtim P, “HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia” (opens in new tab), European Journal of Haematology, vol. 112, no. 3, pp. 392-401, 2024.
- Yazdanpanah O, Benjamin DJ, Vosoughi E, Raad A, Popal M, Kongtim P, “Understanding patient and provider preferences in management of metastatic renal cell carcinoma (mRCC)”, Journal of Clinical Oncology, vol. 42, no. 16_suppl, pp. e16530, 2024.
- Zou J, Kongtim P, Oran B, Srour SA, Greenbaum U, Carmazzi Y, Rondon G, Ciurea SO, Ma Q, Shpall EJ, Champlin RE, Cao K, “Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation” (opens in new tab), Cancer, vol. 129, no. 8, pp. 1205-1216, 2023.
- Lee BJ, Kongtim P, Doh J, Griffin SP, Chan A, O'Brien S, Ciurea SO, Jeyakumar D, “Impact of triple intrathecal prophylaxis in acute lymphoblastic leukemia adults receiving HyperCVAD: A COVID-19 practice change” (opens in new tab), European Journal of Haematology, vol. 111, no. 1, pp. 154-160, 2023.
- Lee BJ, Cao Y, Vittayawacharin P, É'Leima G, Rezk S, Reid J, Brem EA, Ciurea SO, Kongtim P, “Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis” (opens in new tab), European Journal of Haematology, vol. 111, no. 3, pp. 477-484, 2023.
- Kongtim P, Vittayawacharin P, É'Leimat G, “339 - Budesonide Added to Ptcy, Tacrolimus and Mycophenolate Mofetil for Prevention of GI Gvhd in Allogeneic Stem Cell Transplantation”, Transplantation and Cellular Therapy, vol. 29, no. 2, Supplement, pp. S259-S260, 2023.
- Griffin SP, Lee B, Pannunzio N, Doh J, Chan A, Ciurea S, Jeyakumar D, O'Brien SM, Fleischman AG, Naqvi K, Kongtim P, “Treatment outcomes in adults with newly diagnosed B-cell acute lymphoblastic leukemia: A comparison between pediatric-inspired regimens and HyperCVAD at a Hispanic-serving cancer center”, Journal of Clinical Oncology, vol. 41, no. 16_suppl, pp. 7048, 2023.
- Soyfer EM, Chen JH, Kongtim P, Fleischman AG, “An Optimal Dose Finding Study of N-Acetylcysteine in Patients with Myeloproliferative Neoplasms”, Blood, vol. 142, no. Supplement 1, pp. 6443, 2023.
- To AQ, Ciurea SO, Kongtim P, “Acquired Factor V Deficiency: A New Cause of Bleeding in Patients with Chronic Myeloid Leukemia and Extreme Leukocytosis?” (opens in new tab), Acta Haematologica, vol. 146, pp. 543-546, 2022.
- Lee BJ, Griffin SP, Doh J, Chan A, O'Brien S, Jeyakumar D, Ciurea SO, Becker PS, Kongtim P, “CD19-directed immunotherapy use in KMT2A-rearranged acute leukemia: A case report and literature review of increased lymphoid to myeloid lineage switch” (opens in new tab), American Journal of Hematology, vol. 97, no. 12, pp. E439-E443, 2022.
- Vittayawacharin P, Kongtim P, Ciurea SO, “Allogeneic stem cell transplantation for patients with myelodysplastic syndromes” (opens in new tab), American Journal of Hematology, vol. 98, pp. 322-337, 2022.
- Zou J, Kongtim P, Srour SA, Greenbaum U, Schetelig J, Heidenreich F, Baldauf H, Moore B, Saengboon S, Carmazzi Y, Rondon G, Ma Q, Rezvani K, Shpall EJ, Champlin RE, Ciurea SO, Cao K, “Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy” (opens in new tab), Frontiers in Immunology, vol. 13, pp. 1033871, 2022.
- Hwang WY, Kongtim P, Majhail NS, Yao M, “Alternate Donor Transplantation”, Blood Cell Ther, vol. 5, no. Spec Edition, pp. S6-S14, 2022.
- Zou J, Kongtim P, Oran B, Kosmoliaptsis V, Carmazzi Y, Ma J, Li L, Rondon G, Srour S, Copley HC, Partlow D, Ciurea SO, Greenbaum U, Ma Q, Shpall EJ, Champlin RE, Cao K, “Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation” (opens in new tab), Haematologica, vol. 107, pp. 844-856, 2021.
Most Cited Publications
- Ciurea SO, Kongtim P, Soebbing D, Trikha P, Behbehani G, Rondon G, Olson A, Bashir Q, Gulbis AM, Indreshpal K, Rezvani K, Shpall EJ, Bassett R, Cao K, Martin AS, Devine S, Horowitz M, Pasquini M, Lee DA, Champlin RE, “Decrease post-transplant relapse using donor-derived expanded NK-cells” (opens in new tab), Leukemia, vol. 36, pp. 155-164, 2021.
- Kongtim P, Popat U, Jimenez A, Gaballa S, El Fakih R, Rondon G, Chen J, Bueso-Ramos C, Borthakur G, Pemmaraju N, Garcia-Manero G, Kantarjian H, Alousi A, Hosing C, Anderlini P, Khouri IF, Kebriaei P, Andersson BS, Oran B, Rezvani K, et al., “Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia” (opens in new tab), Biology of Blood and Marrow Transplantation, vol. 22, no. 1, pp. 47-53, 2016.
- Ciurea SO, Kongtim P, Varma A, Rondon G, Chen J, Srour S, Bashir Q, Alousi A, Mehta R, Oran B, Popat U, Hosing C, Olson A, Daver N, Konopleva M, Champlin RE, “Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation?” (opens in new tab), Blood, vol. 135, no. 6, pp. 449-452, 2020.
- Kongtim P, Cao K, Ciurea SO, “Donor Specific Anti-HLA Antibody and Risk of Graft Failure in Haploidentical Stem Cell Transplantation” (opens in new tab), Advances in Hematology, vol. 2016, pp. 4025073, 2016.
- Oran B, Kongtim P, Popat U, de Lima M, Jabbour E, Lu X, Chen J, Rondon G, Kebriaei P, Ahmed S, Andersson B, Alousi A, Ciurea S, Shpall E, Champlin RE, “Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation” (opens in new tab), Biology of Blood and Marrow Transplantation, vol. 20, no. 10, pp. 1618-25, 2014.
- Kongtim P, Di Stasi A, Rondon G, Chen J, Adekola K, Popat U, Oran B, Kebriaei P, Andersson BS, Champlin RE, Ciurea SO, “Can a female donor for a male recipient decrease the relapse rate for patients with acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation?” (opens in new tab), Biology of Blood and Marrow Transplantation, vol. 21, no. 4, pp. 713-9, 2015.
- Ciurea SO, Kongtim P, Srour S, Chen J, Soebbing D, Shpall E, Rezvani K, Nakkula R, Thakkar A, Troy EC, Cash AA, Behbehani G, Cao K, Schafer J, Champlin RE, Lee DA, “Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML” (opens in new tab), American Journal of Hematology, vol. 99, no. 5, pp. 890-899, 2024.
- Kongtim P, Parmar S, Milton DR, Perez JMR, Rondon G, Chen J, Chilkulwar AR, Al-Atrash G, Alousi A, Andersson BS, Im JS, Hosing CM, Bashir Q, Khouri I, Kebriaei P, Oran B, Popat U, Champlin R, Ciurea SO, “Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome” (opens in new tab), Bone Marrow Transplantation, vol. 54, no. 6, pp. 839-848, 2019.
- Kongtim P, Lee DA, Cooper LJ, Kebriaei P, Champlin RE, Ciurea SO, “Haploidentical Hematopoietic Stem Cell Transplantation as a Platform for Post-Transplantation Cellular Therapy” (opens in new tab), Biology of Blood and Marrow Transplantation, vol. 21, no. 10, pp. 1714-20, 2015.
- Kongtim P, Vittayawacharin P, Zou J, Srour S, Shaffer B, Shapiro RM, Varma A, McGuirk J, Dholaria BR, McCurdy SR, DeZern AE, Bejanyan N, Bashey A, Furst S, Castagna L, Mariotti J, Ruggeri A, Bailen R, Teshima T, Xiao-Jun H, et al., “ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies” (opens in new tab), Transplantation and Cellular Therapy, vol. 30, pp. 1139-1154, 2024.
This profile was created with the help of AI.
Last updated on 6/2/2026.